A new clinical research study for systemic sclerosis-related ILD is now enrolling!

Systemic sclerosis (SSc, or scleroderma), is a chronic, progressive, autoimmune disease characterized by inflammation and fibrosis of connective tissues throughout the body, including the skin and internal organs. SSc that occurs in the lungs is called SSc-related interstitial lung disease (SSc-ILD).

We are investigating whether an investigational drug, called efzofitimod, can improve (or be an effective form of treatment for) the skin and lung effects caused by SSc-ILD. The clinical trial investigating efzofitimod for the treatment of SSc-ILD is called the EFZO-CONNECT™ Study.

If you are interested in taking part in this clinical trial for SSc-ILD, we are looking for people who:

  • Are ≥ 18 years of age
  • Have a diagnosis of SSc-ILD
  • Have a duration of systemic scleroderma < 4 years
  • Have been taking mycophenolate mofetil of ≥ 2 gm/day for at least 6 months

There are other criteria that you will need to meet to qualify, which the study team will discuss with you.

For further information about the EFZO-CONNECT™ Study, contact SScILD@cssienroll.com or 877-689-4494.

Study details and additional information are available at clinicaltrials.gov (NCT#05892614).

© 2007 - 2024   aTyr Pharma.   Legal   Privacy Policy